Lung cancer: treatment and toxicities

  • Small cell lung cancer
  • Radiotherapy
  • Patient case studies
  • Patient experience

Suitable for nurses, allied health professionals (AHPs) and all clinicians with an interest in lung cancer.

Time Session
9.15 Welcome and introduction 
9.30 Chairperson's welcome
Professor Janelle Yorke, Chief nurse, The Christie NHS Foundation Trust
9.45 Small cell pathway
Emma Halkyard, Lung cancer nurse clinician, The Christie NHS Foundation Trust
10.00 1st-line treatments in extensive stage small cell lung cancer
Professor Raffaele Califano, Consultant in medical oncology, The Christie NHS Foundation Trust
10.30 Research in small cell lung cancers
Dr Laura Molliner, Clinical fellow in medical oncology, The Christie NHS Foundation Trust
10.50 Management of paraneoplastic syndromes in small cell lung cancer
Dr Paul Taylor, Consultant in medical oncology, The Christie NHS Foundation Trust
11.20 Break
11.30 Overview of radiotherapy treatments
Prof Corinne Faivre-Finn, Consultant in clinical oncology, The Christie NHS Foundation Trust
12.00 Importance of molecular testing in non-small cell lung cancer (NSCLC)
Mr Mathew Carter, Scientific officer, The Christie NHS Foundation Trust
12.30 Overview of treatment advances in NSCLC
Dr Yvonne Summers, Consultant in medical oncology, The Christie NHS Foundation Trust
13.00 Lunch 
13.30 Steroid induced psychosis
Dr Asanga Fernando, Consultant liaison psychiatrist, St Georges NHS Foundation Trust
14.00 One Stop Lung Clinic
Sr Karen Peplow, Lung cancer clinical nurse specialist, Manchester University NHS Foundation Trust
14.30 Overview of the Senior adult oncology service
Naomi Farrington, Senior adult oncology service implementation lead, The Christie NHS Foundation Trust
15.00 Break 
15.15 Ruth Strauss Foundation
Ms Deepa Doshi, Head of Mission Services, The Ruth Strauss Foundation
15.45 Patient stories 
16.15 Close 

Takeda

Takeda Oncology aspire to cure cancer, with inspiration from patients and innovation from everywhere.

Delivering on the unique needs of patients, who have limited or ineffective treatment options, is at the centre of everything they do. They live this philosophy through their Patient-Trust-Reputation-Business decision-making framework.

Takeda Oncology strive to provide transformative therapies, developed from ground-breaking science, to dramatically improve patients’ lives.

Grounded in more than 240 years of Japanese heritage, they are built on Takeda’s legacy foundation. They benefit from the international resources of a top biopharmaceutical leader, whilst also being structured for agility. As a patient-driven research and development organisation, Takeda Oncology are collaborative, nimble and fast to meet the needs of the cancer community.

You can learn more about the company on the Takeda onocology website.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, and respiratory and immunology.

AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Bayer

It's an exciting time as Bayer aims to develop products that improve people’s quality of life. They concentrate on the research and development of innovative drugs and novel therapeutic approaches to prioritise targets and pathways, with the potential to impact not just the treatment of common cancers, but rarer cancers as well.

Irwin Mitchell

Irwin Mitchell LLP has over 30 years’ experience in successfully recovering compensation for clients whose lives have been affected by mesothelioma and other asbestos-related illnesses. Their specialist solicitors are based nationwide and have helped and supported several thousand clients after exposure to asbestos through their work, domestic or environmental circumstances. 

They have the largest team of asbestos solicitors in the UK, and have won several landmark victories that have led to significant changes in the law including the first ever successful case of environmental exposure in 1995, and the first settlement including hospice costs as well as compensation.

Sign up to our education events mailing list to be kept up to date with this and future events

Last updated: January 2023